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Abstract
 Cardiometabolic factors are implicated in the aetiology ofIntroduction:
Alzheimer’s disease and may lie on the pathways linking genetic variants to
Alzheimer’s disease across the life course. We examined whether
polygenic risk scores (PRS) were associated with cardiometabolic health
indicators through childhood and adolescence.
In 7,977 participants from the Avon Longitudinal Study ofMethods: 
Parents and Children, we tested whether a PRS for Alzheimer’s disease
was associated with trajectories of cardiometabolic risk factors. We
examined trajectories for height at 1-18 years; lean and fat mass at 9-18
years; systolic and diastolic blood pressure at 7-18 years; glucose and
C-reactive protein at 9-18 years; insulin at 10-18 years; and high and
low-density lipoproteins and triglycerides birth at 18 years. We also
examined birthweight and interleukin-6 (IL-6) at age 9 years and physical
activity at ages 11, 12, and 15 years.
No consistent associations were observed between the PRSResults: 
excluding genetic variants in the apolipoprotein E gene region and
cardiometabolic factors trajectories across childhood and adolescence.
We did not detect evidence to suggest that the PRS forConclusions: 
Alzheimer’s disease acts through childhood and adolescent
cardiometabolic risk factors. Further studies should examine whether these
associations emerge later in adulthood when variation in cardiometabolic
risk factors is likely to be greater.
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Introduction
There is growing evidence from observational studies for a role of 
midlife hypertension, obesity, hyperlipidaemia1, hyperglycaemia2, 
and inflammation3,4 in the aetiology of Alzheimer’s disease. 
Evidence for a role of cardiometabolic risk factors in later life 
is less clear as observed associations are often either null or 
protective1,5,6. This age-dependent change in the direction of the 
associations observed for cardiometabolic risk factors has been 
suggested to potentially reflect selection bias, as fatal cardi-
ometabolic disease events would reduce the risk of being diag-
nosed with Alzheimer’s disease, which usually occurs late in life7. 
Another possible explanation for these findings is reverse causa-
tion, due to the potential presence of undiagnosed Alzheimer’s 
disease (which has been shown to be associated with a lowering 
of blood pressure5 and weight loss6) at the time of assessment 
of the cardiometabolic risk factors.
Large genetic consortia have identified common genetic vari-
ants associated with late-onset Alzheimer’s disease8, with the ε4 
allele of the apolipoprotein E (ApoE) gene conferring the great-
est risk, increasing the risk up to twelvefold9. ApoE adversely 
affects lipid profiles10 and elevates the risk of coronary artery 
disease11. Although the genetic variants (apart from ApoE4) indi-
vidually increase risk by a small amount, they can be summarised 
to construct a polygenic risk score (PRS) for Alzheimer’s dis-
ease which has a good ability to correctly classify those with and 
without the disease (area under the receiver operating characteris-
tic curve [AUROC] = 78.2% with a P-value threshold of ≤0.5)12. 
Apart from ApoE, the relationship of these genetic variants to 
cardiovascular disease is uncertain.
PRS can be used to investigate potential prodromal phenotypes 
and or pathways through which the variants influence Alzheim-
er’s disease risk. There are very few studies13,14 examining the 
association between cardiometabolic risk factors in early life, 
likely due to the long follow-up required across the life course. 
We tested the hypothesis that a PRS for Alzheimer’s disease 
(beyond the ApoE gene) acts through cardiometabolic pathways 
in children and adolescents.
Methods
Participants
The Avon Longitudinal Study of Parents and Children (ALSPAC) 
is a prospective birth cohort which recruited pregnant women with 
expected delivery dates between April 1991 and December 1992 
from Bristol UK15,16. A total of 14,541 pregnant mothers were 
initially enrolled, from which 13,867 live births occurred in 13,761 
women. Including two later rounds of recruitment, there were 
15,445 eligible children. Information on health and development 
of children and their parents were collected from regular clinic 
visits and completion of questionnaires. Research clinics were 
held when the participants were approximately seven, nine, 10, 
11, 13, 15, and 18 years old. The study website contains details 
of all the data that is available through a fully searchable data 
dictionary: http://www.bris.ac.uk/alspac/researchers/data-access/
data-dictionary/. Ethical approval was obtained from the ALSPAC 
Law and Ethics Committee and the Local Ethics Committees.
Cardiometabolic measures
Anthropometry. Birthweight was obtained from obstetric records. 
At the clinics between 4 months and 5 years, crown-heel length was 
measured using a Harpenden Neonatometer and from 25 months 
onwards, standing height was measured using a Leicester Height 
Measure. From age 7 years, all children were invited to yearly 
clinics, where measurements of standing height were obtained 
using the Harpenden Stadiometer. At each clinic at ages nine, 11, 
13, 15, and 18 years, whole body less head, and central fat and 
lean mass were derived from whole body dual energy X-ray absorp-
tiometry (DXA) scans evaluated using a Lunar prodigy narrow 
fan beam densitometer.
Cardiometabolic and inflammatory factors. At each clinic (ages 
seven, nine, 10, 11, 12, 15, and 18), systolic and diastolic blood 
pressure were measured at least twice. The mean of two measure-
ments was used in the analysis. Insulin was obtained from cord 
blood at birth. Non-fasting glucose was also measured at age 
seven as part of the metabolomics assays, using nuclear mag-
netic resonance spectrometry (NMR). Fasting glucose and insulin 
were also available for a random 10% of the cohort at age nine 
years, as well as research clinics at 15 and 18 years. Triglycerides, 
high-density lipoprotein (HDL-c), and total cholesterol (TC) were 
available from cord blood and venous blood, subsequently. 
Non-fasting samples were available from research clinics at 
ages 7 and 9 years; fasting measures were available from clin-
ics at 15 and 18 years. Non-HDL-c was calculated by deduct-
ing HDL-c from total cholesterol. Hence, the trajectories of 
triglycerides, HDL-c, non-HDL-c, insulin and glucose are a 
combination of measures from cord blood, fasting, non-fasting 
bloods, and NMR. Interleukin-6 (IL-6) was measured by ELISA 
(R&D systems, Abingdon, UK) and available at 9 years, and 
C-reactive protein (CRP) was measured by automated particle- 
enhanced immunoturbidimetric assay (Roche UK, Welwyn 
Garden City, UK). CRP levels were measured at 9, 15 and 18 
years of age. More details of measurement assays and protocols 
are provided as Extended data17.
Physical activity. All children who attended the clinic at ages 
11, 13, and 15 years were asked to wear an accelerometer 
for 7 days. More details of the physical activity measures are 
provided as Extended data17.
Genetic data
DNA samples from 9,912 ALSPAC children were genotyped on 
the Illumina HumanHap550-quad single nucleotide polymor-
phism (SNP) array genotyping platform. After quality control 
assessment methods, imputation, and restriction to 1 child per 
family, genetic data was available for 7,977 individuals. More 
details are available in Extended data17.
Statistical analysis
Generating polygenic risk scores. PRS were computed 
according to the method described by the International Schizo-
phrenia Consortium18, based on the summary statistics from 
the genome-wide association study (GWAS) of Alzheimer’s 
disease by the IGAP consortium8. Details about IGAP are in the 
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Extended data17. PRS were created for the significance 
thresholds: 5×10-8 (genome-wide significance threshold), 5×10-2, 
and 5×10-1, including a different number of SNPs (Table S1 
of Extended data17). A list of the 17 SNPs used to gener-
ate the PRS at the genome-wide significant threshold is pro-
vided in Table S2 of the Extended data17. This threshold was 
chosen for the main analysis since it includes the most strongly 
associated SNPs. However, less stringent p-value thresholds 
can explain more of the Alzheimer’s disease variance. Results 
for the other thresholds are available in the Extended data17. 
As ApoE is involved in lipid homeostasis by mediating lipid 
transport19, the main analysis used scores excluding ApoE. 
Modelling trajectories of cardiometabolic risk factors. Chil-
dren with at least one measure were included in the multilevel 
models to minimise selection bias, under a missing at random 
assumption20–23. All trajectories were estimated using linear 
spline multilevel models (two levels: measurement occa-
sion and individual). The optimal linear spline model for each 
cardiometabolic risk factor was based on previous work21–27. 
All trajectories were modelled in MLwiN version 3.0128, called 
from STATA version 1429 using the runmlwin command30. All 
trajectories were centred on the lowest age (in whole years) 
at the first available measure and mean PRS. Variables with a 
skewed distribution (triglycerides, fat mass, CRP) were (natural) 
log transformed. Fat and lean mass were adjusted for height with 
the use of a time- and sex-varying height covariate derived in 
previous literature22,23,27, which was centred on the mean of this 
derived covariate. The non-linearity of height trajectories was 
modelled using fractional polynomials to find the best fitting 
function of age. Further details of trajectories are in Extended 
data17. We incorporated a fixed effect for the PRS in each trajec-
tory along with an interaction term for the PRS and the linear 
splines or fractional polynomials. The coefficients represent the 
mean difference in the risk factor at baseline per one standard 
deviation (SD) higher PRS, and the mean change in the risk fac-
tor per year, or per year within each linear spline period, per 
one SD higher PRS. Results including the logged risk factors 
are interpreted as mean percentage change rather than mean dif-
ference. The mean trajectory was allowed to differ between 
males and females by including an interaction between gender 
and age. Results were interpreted according to the American 
Statistical Association guidance31,32.
Modelling risk factors with sparse measures. Due to the 
sparse measures for birthweight, insulin, IL-6, and MVPA, 
linear regression models were used to estimate the associa-
tion between the PRS and these measures. Measures from the 
clinic with the highest number of participants were used for the 
analysis, where applicable. As insulin, IL-6 and MVPA had a 
skewed distribution, they were transformed using the natural 
logarithm. Models were adjusted for age, sex and the first three 
ancestry-informative principal components.
Sensitivity analyses
We examined the associations between the PRS including only 
the two SNPs tagging the ApoE region (rs7412 and rs429358) 
and the PRS excluding ApoE and cardiometabolic risk factors 
at different p-value thresholds. To examine if our results were 
changed by the inclusion of non-fasted bloods in some of the 
clinics, we repeated analyses excluding all participants who 
reported eating four hours prior to the 15 and 18-year clin-
ics. To test the generalisability of our results, we investigated 
the characteristics of individuals in the analysis of insulin 
(model with the fewest individuals and repeated measures) to 
those excluded from this analysis (individuals with no genetic or 
cardiometabolic data).
An earlier version of this article can be found on bioRxiv 
(DOI: https://doi.org/10.1101/580548).
Results
Descriptive statistics
The number of children used in the models ranged from 699 to 
6,953 individuals. Descriptive and model fit statistics are in Sup-
plementary Table S3–Table S4 of the Extended data17. The 
household social class of children in the analysis of glucose 
(model with the smallest sample size) was higher compared to 
children excluded due to missing data (19.6% professional vs. 
12.3% professional, p<0.0001). Furthermore, the prevalence of 
maternal smoking during pregnancy was lower in the included 
sample compared to the excluded sample (17.5% vs 28.2%, 
p<0.0001) (Supplementary Table S5 of the Extended data17).
Main analysis
Figure 1–Figure 3 show the mean trajectories of anthropometry, 
blood pressure, and blood-based biomarkers measures, respec-
tively, alongside the association between the PRS and each of these 
cardiometabolic risk factor trajectories. At the genome-wide 
significant p-value threshold, there was weak evidence of associa-
tion of a PRS with birthweight (Table S6.1 of Extended data17) 
and height trajectories (Figure 1A). At age nine years, there was 
weak evidence that a PRS was associated with a higher height-
adjusted fat mass (β: 0.59%; 95% confidence interval [CI]: -0.92, 
2.11, Table S6.3 of Extended data17) and height-adjusted lean 
mass (β: 0.04 kg; 95% CI: -0.03, 0.11, Table S6.3 of Extended 
data17). In line with these results, there was little evidence 
of an association between the PRS, SBP, glucose, trig-
lycerides, non-HDL, HDL-c and CRP (Figure 3). There 
was stronger evidence of an association with higher DBP 
(β: 0.19 mmHg; 95% CI: 0.02, 0.37) at age 7 years and lower 
DBP (β: -0.05 mmHg; 95% CI: -0.09, -0.003) from ages 7 to 
12 years (Table S6.4). Cross-sectional models showed weak 
evidence of association with higher insulin, IL-6, and MVPA 
levels (Table S6.8–6.9 of Extended data17). The direction of 
effect between time periods in multilevel models was consist-
ent only for CRP (Table S6.7 of Extended data17) and MVPA 
(Table S6.9 of Extended data17). For all risk factors except for DBP, 
the 95% CIs spanned the null.
Sensitivity analyses
Sensitivity analyses comparing the results for the PRS at dif-
ferent p-value thresholds used PRS excluding ApoE. Further 
analyses comparing the results with the PRS including/excluding 
ApoE were performed using the genome-wide significant 
threshold. The effect size for the β-coefficients was larger for 
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Figure 1. Mean trajectories of anthropometric measures and mean change in anthropometric measures per 1-SD increase in polygenic 
risk scores (PRS) from ages 9–18 years in ALSPAC. (A) Height, (B) lean mass, and (C) fat mass. The shaded areas in the left graphs and 
the bars in the right graphs represent 95% confidence intervals, respectively.
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Figure 2. Mean trajectories of blood pressure measures and mean change in blood pressure measures per 1-SD increase in polygenic 
risk scores (PRS) from ages 7–18 years in ALSPAC. (A) Systolic blood pressure and (B) diastolic blood pressure. The shaded areas in the 
left graphs and the bars in the right graphs represent 95% confidence intervals, respectively.
risk factors such as height, lean mass, triglycerides and CRP at 
the more liberal PRS thresholds. A higher PRS was associated 
with shorter stature at the more liberal thresholds at ages 
4–10 years (β: -0.15 cm; 95% CI: -0.20, -0.01 at age 5 years 
and p≤5×10-1, Table S8.2 of Extended data17). A higher PRS 
was associated with lower lean mass at ages 9 and 15–18 years 
(β: -0.06 kg/yr; 95% CI: -0.11, -0.02 at age 15 years and 
p≤5×10-1, Table S8.3 of Extended data17). The direction of 
effect differed between the genome-wide significant threshold 
and the more liberal thresholds for some risk factors (Table S7– 
Table S10 of Extended data17). PRS which incorporated the 
ApoE region were associated with cardiometabolic risk factors 
such as HDL-c, non-HDL-c, DBP, and CRP as expected by the 
role of ApoE in lipid homeostasis. There was strong evidence 
of association between a PRS including the ApoE region and 
higher non-HDL-c levels at birth (β: 0.03; 95% CI: 0.01, 0.04, 
Table S9.6 of Extended data17) and from ages 9–12 years 
(β: -0.003; 95% CI: -0.01, -0.0005). There was also strong 
evidence that a PRS with ApoE was associated with lower 
HDL-c levels at birth (β: -0.01 mmol/l; 95% CI: -0.02, -
0.005, Table S9.6 of Extended data17) and from birth to 
age 7 years (β: -0.002 mmol/l yr; 95% CI: -0.003, -0.0004), and 
higher HDL-c levels from ages 7–18 years (β: 0.001 mmol/l yr; 
95% CI: 0.0002, 0.002). For a 1 SD increase in the PRS, 
CRP levels were 8.60% (95% CI; -11.86, -5.21, Table S9.7 of 
Extended data17) lower at age 9 years. To compare fasting/ 
non-fasting biomarkers, we used the PRS excluding ApoE at the 
genome-wide significant threshold. The associations observed 
between non-fasted and fasted bloods were similar for all 
examined blood-based biomarkers (Tables S10 of Extended 
data17).
Discussion
To our knowledge, this is the first study examining whether a PRS 
for Alzheimer’s disease was associated with trajectories of cardi-
ometabolic risk factors through childhood and adolescence. We 
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Figure 3. Mean trajectories of blood-based biomarkers and mean change per 1-standard deviation increase in PRS. (A) Glucose from 
ages 7–18 years, (B) triglycerides, (C) non-high-density lipoprotein-cholesterol (HDL-c), and (D) HDL-c from ages 0–18 years. (E) C-reactive 
protein (CRP) from ages 9–18 years. The shaded areas in the left graphs and the bars in the right graphs represent 95% confidence intervals, 
respectively.
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examined these associations firstly to test whether associations 
may emerge early in the life course, and secondly to minimise 
selection bias due to attrition from cardiometabolic-associated 
morbidity and mortality. We did not find any consistent evidence 
to suggest that the PRS for Alzheimer’s disease was associated 
with cardiometabolic risk factors in childhood or adolescence. 
The predominantly null results at the genome-wide significant 
p-value threshold may indicate that either the PRS for 
Alzheimer’s disease does not operate through cardiometabolic 
pathways or that it operates partly through cardiometabolic 
pathways, but the associations emerge much later in life.
In our sensitivity analyses, we observed associations between the 
more liberal PRS and some of the cardiometabolic risk factors 
(such as height, lean mass, triglycerides, insulin, and CRP). For 
example, we found evidence of association with shorter stat-
ure from ages 4–10 years, lower lean mass at ages 9 years and 
from ages 15–18 years (at p-value threshold p≤5×10-1). As these 
PRS include many genetic variants which are weakly associated 
with Alzheimer’s disease and the associations observed are 
dissimilar in the direction of effect for all time-points, there is a 
chance that the associations may be attributed to horizontal plei-
otropy where the PRS is associated with a range of independent 
phenotypes. Furthermore, the effects of the PRS at each p-value 
threshold cannot be disentangled since PRS at higher p-value 
thresholds include all SNPs from PRS at lower p-value thresh-
olds. We also found evidence of an association between the 
PRS for Alzheimer’s disease (including the ApoE region) and 
HDL, non-HDL, CRP, and triglyceride levels, but the direction of 
effect was not consistent across all time-points.
Comparison to other studies
Longitudinal cohort studies with prospective phenotypic data 
through early life into adulthood and clinical diagnosis of Alzhe-
imer’s disease are scarce. Studies researching developmental 
factors such as height are the only source of data on early life 
exposures. It has been hypothesised that suboptimal foetal devel-
opment, indexed by small birth weight/size may result in perma-
nent changes in the structure, metabolism of the organs through 
various biological mechanisms33. By contrast, positive asso-
ciations have been found between several cardiometabolic risk 
factors in midlife and Alzheimer’s disease1, with higher DBP 
and SBP increasing the risk of Alzheimer’s disease5, independ-
ent of the ApoE genotype. A positive association has also been 
found for BMI trajectories in midlife and Alzheimer’s disease34.
A study of PRS for Alzheimer’s disease in adults with 
Alzheimer’s disease and/or a family history of Alzheimer’s dis-
ease identified an inverse association between a PRS, hyper-
tension and stroke, but no associations for type 2 diabetes and 
heart disease35. Studies in children have only focused on ApoE, 
where there is an established linear relationship between ApoE 
and LDL in children and adults36,37. Although the ApoE region 
is the largest genetic risk factor for Alzheimer’s disease, it 
is also strongly independently associated with cardiometabolic 
risk factors (primarily lipids), making it difficult to exclude 
pleiotropy as an explanation for any observed findings (i.e. ApoE 
may be associated with cardiometabolic risk independently of 
Alzheimer’s disease. Contrary to a recent GWAS38, we did not 
find an association between ApoE4 and physical activity. In 
agreement with our results, a study found a negative genetic 
correlation between height and dementia, suggesting our find-
ings for height at liberal thresholds may be due to shared genetic 
pathways39.
Strengths and limitations
We performed our analysis in children and adolescents to exam-
ine whether genetic risk for Alzheimer’s disease operates through 
cardiometabolic pathways in early in the life course and to 
minimise selection bias due to attrition from cardiometabolic- 
associated morbidity and mortality. Additionally, the use of 
genetic scores makes confounding by social and lifestyle 
characteristics highly unlikely. Our study benefits from a well-
characterised cohort with repeated measures of a range of 
cardiometabolic risk factors over a course of 18 years. The 
use of multilevel models enabled us to account for the clus-
tering of repeated measurements within individuals and the 
correlation between repeated measurements over time.
However, as genetic scores explain a small proportion of vari-
ance in the outcome, it is highly likely we may have been 
underpowered to detect small polygenic effects on the exam-
ined cardiometabolic risk factors. For this reason, we did not 
correct our results for multiple testing, as our findings were largely 
null. Further limitations include the use of non-fasting and fasting 
bloods for some of the examined risk factors and the availability 
of measures from birth for only four of the risk factors. How-
ever, the estimates for fasted and non-fasted bloods were simi-
lar in our sensitivity analyses. Furthermore, PRS were derived 
from a GWAS of European individuals and our study was also 
conducted in individuals of European ancestry; hence, these 
results may not be generalizable to other populations.
Conclusion
We found little evidence to suggest that the combined genetic 
effects conferring an increased risk for Alzheimer’s disease were 
associated with cardiometabolic risk factors, beyond the ApoE 
effect. As this is the first study to examine these associations 
through childhood and adolescence, these findings should be rep-
licated in other large birth cohorts to examine whether the genetic 
risk for Alzheimer’s disease can be captured in early childhood, 
or whether it becomes phenotypically manifest in adulthood.
Data availability
Underlying data
ALSPAC data access is through a system of managed open 
access. The steps below highlight how to apply for access 
to the data included in this article and all other ALSPAC data:
1.    Please read the ALSPAC access policy (pdf, 800 kB) which 
describes the process of accessing the data and samples 
in detail, and outlines the costs associated with doing so.
2.    You may also find it useful to browse our fully search-
able research proposals database, which lists all research 
projects that have been approved since April 2011.
3.    Please submit your research proposal for consideration 
by the ALSPAC Executive Committee. You will receive a 
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response within 10 working days to advise you whether 
your proposal has been approved.
Extended data
Open Science Framework: Polygenic risk score for Alzheimer’s 
disease and trajectories of cardiometabolic risk factors in 
children.2019. https://doi.org/10.17605/OSF.IO/3ND8U17.
This project contains supp_biorxiv.docx, which contains the 
following extended data: 
•    Supplementary methods
•    Table S1. Number of SNPs included in PRS at different 
p-value thresholds including/excluding the ApoE region.
•    Table S2. Genome-wide significant SNPs included in the 
genetic risk score based on IGAP GWAS Stage 1.
•    Table S3. Descriptive statistics of cardiometabolic risk 
factors.
•    Table S4. Details of model selection for each cardiometa-
bolic risk factor.
•    Table S5. Characteristics at birth of the mothers of chil-
dren included in models of glucose (risk factor with 
least individuals).
•    Table S6. Associations between cardiometabolic risk 
factors and PRS for Alzheimer’s disease at p≤5×10-8.
•    Table S7. Associations between cardiometabolic risk 
factors and PRS for Alzheimer’s disease at p≤5×10-2.
•    Table S8. Associations between cardiometabolic risk 
factors and PRS for Alzheimer’s disease at p≤5×10-1.
•    Table S9. Associations between cardiometabolic risk 
factors and PRS for Alzheimer’s disease (including the 
ApoE region) at p≤5×10-8.
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
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